MARKET

MRSN

MRSN

Mersana Therapeutics Inc
NASDAQ
0.4501
-0.0289
-6.03%
Opening 10:11 03/18 EDT
OPEN
0.4654
PREV CLOSE
0.4790
HIGH
0.4729
LOW
0.4501
VOLUME
527.32K
TURNOVER
--
52 WEEK HIGH
5.11
52 WEEK LOW
0.4417
MARKET CAP
56.10M
P/E (TTM)
-0.7971
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MRSN last week (0310-0314)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Revelation Biosciences (REVB)
TipRanks · 03/10 09:40
Weekly Report: what happened at MRSN last week (0303-0307)?
Weekly Report · 03/10 09:04
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts
Simply Wall St · 03/08 12:58
Positive Outlook for Mersana Therapeutics Amid Strategic Developments and Financial Stability
TipRanks · 03/05 03:35
Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)
TipRanks · 03/04 12:38
Positive Outlook for Mersana Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position
TipRanks · 03/04 11:19
Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations
Simply Wall St · 03/04 11:07
More
About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Webull offers Mersana Therapeutics Inc stock information, including NASDAQ: MRSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRSN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRSN stock methods without spending real money on the virtual paper trading platform.